P-selectin gene genotypes or haplotypes and cardiovascular complications in type 2 diabetes mellitus

2006 ◽  
Vol 16 (6) ◽  
pp. 418-425 ◽  
Author(s):  
G. Zalewski ◽  
E. Ciccarone ◽  
A. Di Castelnuovo ◽  
F. Zito ◽  
F. Capani ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Complications

scholarly journals Genetic Susceptibility Contributes to Renal and Cardiovascular Complications of Type 2 Diabetes Mellitus

Hypertension ◽  
2006 ◽  
Vol 48 (1) ◽  
pp. 8-13 ◽  
Author(s):  
Barry I. Freedman ◽  
Donald W. Bowden ◽  
Michèle M. Sale ◽  
Carl D. Langefeld ◽  
Stephen S. Rich
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Genetic Susceptibility ◽  
Cardiovascular Complications

scholarly journals INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUS

2019 ◽  
Vol 6 (1) ◽  
pp. 38-42
Author(s):  
B.O. Shelest
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Essential Hypertension ◽  
Interleukin 6 ◽  
Inflammatory Marker ◽  
Cardiovascular Complications ◽  
The Relationship ◽  
Diabetes And Obesity

INTERLEUKIN LEVELS IN PATIENTS WITH ESSENTIAL HYPERTENSION COMBINED WITH TYPE 2 DIABETES MELLITUSShelest B.O.The problem of combined course of hypertension of diabetes mellitus type 2 and obesity is becoming more common. This variant of comorbidity crucially increases the risk of cardiovascular complications. Inflammation is considered as an important link between the progression of hypertension and the development of adverse events. This study is devoted to the question of the relationship between the pro-inflammatory marker interleukin-6 and the increased blood pressure in patients with concomitant diabetes and obesity. The treatment of such patients with combined pathology remains the actual and difficult issue of medical practice. The article analyses the dynamics of interleukin-6 in the process of treatment with a fixed triple antihypertensive combination. Key words: hypertension, interleukin-6, type 2 diabetes mellitus, obesity. РІВНІ ІНТЕРЛЕЙКІНІВ У ХВОРИХ НА ГІПЕРТОНІЧНУ ХВОРОБУ У ПОЄДНАННІ З ЦУКРОВИМ ДІАБЕТОМ 2 ТИПУ Шелест Б.О.Все більшого поширення набуває проблема поєднаного перебігу гіпертензії цукрового діабету 2 типу та ожиріння. Такий варіант коморбидности різко підвищує ризик кардіоваскулярних ускладнень. Важливою ланкою в прогресуванні гіпертензії і розвитку несприятливих подій відводиться запаленню. Дана робота присвячена питанню залежності прозапального маркера інтерлейкіну-6 і підвищених цифр артеріального тиску у хворих з супутнім цукровим діабетом 2 типу і ожирінням. Актуальним і складним питанням медичної практики залишається лікування таких пацієнтів з поєднаною патологією. У статті аналізується динаміка інтерлейкіну-6 в процесі лікування потрійною фіксованою антигіпертензивною комбінацією.Ключові слова: гіпертонічна хвороба, інтерлейкін-6, цукровий діабет 2 типу, ожиріння. УРОВЕНЬ ИНТЕРЛЕЙКИНОВ У ПАЦИЕНТОВ С ГИПЕРТОНИЧЕСКОЙ БОЛЕЗНЬЮ В СОЧЕТАНИИ С САХАРНЫМ ДИАБЕТОМ 2 ТИПА. Шелест Б.А.Все большее распространение приобретает проблема сочетанного течения гипертензии сахарного диабета 2 типа и ожирения. Такой вариант коморбидности резко повышает риск кардиоваскулярных осложнений. Важным звеном в прогрессировании гипертензии и развитии неблагоприятных событий отводится воспалению. Даннаяработапосвящена вопросу зависимости провоспалительного маркера интерлейкина-6 и наличием повышенных цифр артериального давления у больных с сопутствующим сахарным диабетом и ожирением. Актуальным и сложным вопросом медицинской практики остается лечение таких пациентов с сочетанной патологией. В статье анализируется динамика интерлейкина-6 в процессе лечения фиксированной тройной антигипертензивной комбинацией. Ключевые слова: гипертоническая болезнь, интерлейкин-6, сахарный диабет 2 типа, ожирение.

scholarly journals First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients

2015 ◽  
Vol 19 (1) ◽  
pp. 89-96 ◽  
Author(s):  
Karina Oganesovna Galstyan ◽  
Liudmila Viktorovna Nedosugova ◽  
Nina Alexandrovna Petunina ◽  
Julia Alexandrovna Trakhtenberg ◽  
Natalia Vadimovna Vostokova ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Cardiovascular Complications ◽  
Dose Titration ◽  
Incretin Mimetics ◽  
Dipeptidyl Peptidase 4 ◽  
Metformin Group ◽  
The Difference

Introduction.In the early 2000s, in type 2 diabetes mellitus (T2DM) treatment, a fundamentally new class of drugs appeared—the incretin mimetics. The use of dipeptidyl peptidase-4 (DPP-4) inhibitors allowed the safety of the T2DM therapy to be increased by reducing several parameters, including hypoglycaemia incidences, risks of cardiovascular complications and weight gain. Market approval of a new Russian drug in this group will ensure modern, efficient and affordable care for our patients.Aim.To study the efficacy and safety of a new DPP-4 inhibitor (gosogliptin) in comparison with that of vildagliptin as monotherapy as well as in combination with metformin in patients with T2DM who were not previously treated with drug therapy.Materials and methods.The study SRX-1374-02 involved 299 patients. In total, 149 patients were randomised to the gosogliptin group and 150 were randomised to the vildagliptin group. The groups were comparable with respect to baseline characteristics. In the first 12-week stage, patients received treatment with one of the study drugs as monotherapy. The decision was then made whether to continue the monotherapy regimen or to add metformin during the next 24 weeks. Dose titration of the study drugs and the addition of metformin were performed on the basis of glycaemia levels. The total treatment duration was 36 weeks.Results.After 12 weeks of monotherapy, НbА1с levels significantly decreased by -0.93% and -1.03% in the gosogliptin and vildagliptin groups, respectively. After the administration of combination therapy the decrease in НbА1с continued and was -1.29% in the gosogliptin + metformin group and -1.35% in the vildagliptin + metformin group when compared with baseline values. The difference in НbА1с reduction between the groups during both treatment periods was ≤0.1% (upper level of CI 0.4%), which led to the conclusion about the superior efficacy of gosogliptin over that of vildagliptin as monotherapy and in combination with metformin. By the end of the 36-week treatment period, НbА1с reached the target level of ≤7.0% in 56.4% and 55.4% of patients in the gosogliptin and vildagliptin groups, respectively (statistically significant differences between treatment groups were not found, p = 0.74).Conclusion.The results showed that gosogliptin is an effective hypoglycaemic agent from the group of DPP-4 inhibitors and can be recommended for use in patients with T2DM both as monotherapy and in combination with metformin.

scholarly journals Extracellular vesicle-shuttled miRNAs: a critical appraisal of their potential as nano-diagnostics and nano-therapeutics in type 2 diabetes mellitus and its cardiovascular complications

Theranostics ◽  
2021 ◽  
Vol 11 (3) ◽  
pp. 1031-1045
Author(s):  
Francesco Prattichizzo ◽  
Giulia Matacchione ◽  
Angelica Giuliani ◽  
Jacopo Sabbatinelli ◽  
Fabiola Olivieri ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Critical Appraisal ◽  
Extracellular Vesicle ◽  
Cardiovascular Complications
Sign in / Sign up

Export Citation Format

Share Document